Autonomix Medical Inc. (NASDAQ: AMIX) is leading the charge to disrupt the $12 Trillion Dollar Healthcare Industry with the integration of A.I.

The field of electrophysiology has seen rapid growth as of late, and with continuous innovation, more opportunities are emerging. As the industry continues to surge, AMIX is looking to make a name for themselves.


Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

Autonomix Medical Inc.


About The Company

Autonomix Medical, Inc. is a medical device company that has advanced innovative technologies to revolutionize how diseases surrounding the nervous system are treated. 

The company’s staple technology does not have a name, but the platform consists of a catheter-based microchip sensing array that can detect and separate neural signals with 3,000x greater sensitivity than technologies currently available.

This technology has the chance to enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system, for the first time… EVER!

AND, their technology acts as a precision-guide smart-bomb, allowing medical professionals to find ultra specific target nerves that are misfiring through ablation or burning, ultimately eliminating the accompanying pain.

…until NOW.

Autonomix’s mission is to improve the quality of millions of lives by empowering the revolution of nerve-targeted treatments.

With AMIX’s groundbreaking technology, they have the means to enable new procedures that were never before possible.

BUT, the company’s strong fundamentals aren’t the only thing to get excited about…


The recent increase in volume and approaching MACD bullish crossover for $AMIX signal strong market interest and potential for significant rallies in this burgeoning sector, which has global implications!

Volume Increase: The recent increase in volume for June indicates heightened market interest and potential for a bullish trend. The volume spike suggests strong buying interest, which could drive the stock price higher.

Technical Indicators: The MACD is close to crossing into bullish territory, which suggests that institutional participation might be strengthening and there is a potential for future rallies. This indicator is crucial for identifying momentum and potential trend reversals.

Share Float: With a float of only 8.19 million shares and 18.85 million outstanding, $AMIX is poised for significant growth. The low float can amplify price movements, especially with positive catalysts, making it an attractive option for investors.

With a globally impactful approach and recent market activities, investors should consider $AMIX for its growth potential. This stock is a "diamond in the rough" and may rally on relatively low volume, especially if there are regulatory catalysts introduced into the market's view.


Target #1: $1.85 (37.04%)

The $1.85 level represents a critical price range where the stock previously encountered resistance in June. This level could serve as a stable base for the stock to regain its upward momentum.

Target #2: $2.35 (+74.07%)

During early May, the stock exhibited significant upward movement, attempting to reach $2.35 before facing rejection. Achieving this target again would signify strong market confidence and potential for further growth, assuming sufficient buying interest.

Potential Support: $1.15 - $1.38 area

The $1.15 - $1.38 area is identified as a potential support, providing a solid foundation for the stock in case of a downside move.

These 5 key points outline the potential of a healthcare x tech innovator like Autonomix ($AMIX):

New Tech = More Results: Autonomix created leverage in the healthcare industry to scale results at unbelievable pace. This leverage gives them significant strategic advantage in a multi-trillion dollar industry that’s run by dinosaurs.

Growing Healthcare Market: The healthcare industry is experiencing rapid growth, with global expenditures projected to reach $12 trillion. Autonomix is continuing to drive substantial revenue growth and market share.

Personalized Care is the Future: AI integration creates the potential to continually learn, adjust, and improve healthcare offerings to each individual. If leveraged correctly, Autonomix can capitalize on this and gain a first mover advantage.

They’re Early: The integration of AI in healthcare is still in its early stages and will take time to develop. Being early to the party provides significant room for growth. As Autonomix continues to innovate and expand its product offerings, it has the potential to capture a larger market share and drive long-term investor value.

Leadership is Everything: The company has focused on merging autonomous solutions with an archaic healthcare industry. This is no small task and will require a strong leader. The recent appointment of Brad Hauser was a strategic move in the direction of innovation. 

Autonomix Medical Inc.


Autonomix Upgrades Leadership Team with CEO Appointment

Brad Hauser - CEO

“Mr. Hauser is a globally renowned medical technology innovation leader and seasoned executive with more than 20 years of experience building teams that bring unique energy-based technologies from concept, through design validation, clinical studies, regulatory approvals, manufacturing, and commercialization”

“Hauser has been a visionary leader for various medical technologies that have traded a broad range of diseases.”

Mr. Hauser’s most recent tenure was as the COO at Beauty Health, a skin-health company that acquired the likes of Soliton Inc., ZELTIQ Aesthetics, and Reliant Technologies.



Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at

By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.

This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.

Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.

The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

Compensation: Pursuant to an agreement between Virtus Media LLC and third party, Virtus Media LLC has been hired by third party for a period beginning on 2024-06-18 and ending 2024-06-25 to publicly disseminate information about NASDAQ: AMIX via digital communications. We have been paid thirteen thousand USD.